US team gets green-light for lymphatic agent trial
This article was originally published in Clinica
The US FDA has given researchers at the University of California, San Diego Cancer Center, the go-ahead to begin a clinical trial of a radiolabelled agent that could help doctors diagnose breast cancer patients more accurately.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.